BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 35618286)

  • 21. The anti-hepatocellular carcinoma effects of polysaccharides from
    Li GL; Tang JF; Tan WL; Zhang T; Zeng D; Zhao S; Ran JH; Li J; Wang YP; Chen DL
    Food Funct; 2023 Apr; 14(7):3155-3168. PubMed ID: 36883482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
    Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Fan JB; Ke AW; Fan J
    J Hepatol; 2022 Jul; 77(1):163-176. PubMed ID: 35219791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quercetin/Anti-PD-1 Antibody Combination Therapy Regulates the Gut Microbiota, Impacts Macrophage Immunity and Reshapes the Hepatocellular Carcinoma Tumor Microenvironment.
    Wu R; Xiong J; Zhou T; Zhang Z; Huang Z; Tian S; Wang Y
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):327. PubMed ID: 38179731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tannins in Terminalia bellirica inhibits hepatocellular carcinoma growth via re-educating tumor-associated macrophages and restoring CD8
    Chang Z; Zhang Q; Hu Q; Liu Y; Zhang L; Liu R
    Biomed Pharmacother; 2022 Oct; 154():113543. PubMed ID: 36057223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HMGA1 Promotes Macrophage Recruitment via Activation of NF-
    Chen J; Ji K; Gu L; Fang Y; Pan M; Tian S
    J Immunol Res; 2022; 2022():4727198. PubMed ID: 35785026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting of Annexin A1 in Tumor-associated Macrophages as a therapeutic strategy for hepatocellular carcinoma.
    Song Z; Wang X; Liu X; Luo Y; Qiu J; Yin A; Liu Y; Yi H; Xiao Z; Li A
    Biochem Pharmacol; 2023 Jul; 213():115612. PubMed ID: 37209858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-b-value DWI to evaluate the synergistic antiproliferation and anti-heterogeneity effects of bufalin plus sorafenib in an orthotopic HCC model.
    Guo R; Lu F; Lin J; Fu C; Liu M; Yang S
    Eur Radiol Exp; 2024 Mar; 8(1):43. PubMed ID: 38467904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetrastigma polysaccharide reprogramming of tumor-associated macrophages via PPARγ signaling pathway to play antitumor activity in breast cancer.
    Liu X; Liu X; Mao W; Guo Y; Bai N; Jin L; Shou Q; Fu H
    J Ethnopharmacol; 2023 Oct; 314():116645. PubMed ID: 37196813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors.
    Yang Y; Ye YC; Chen Y; Zhao JL; Gao CC; Han H; Liu WC; Qin HY
    Cell Death Dis; 2018 Jul; 9(8):793. PubMed ID: 30022048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased OIT3 in macrophages promotes PD-L1 expression and hepatocellular carcinogenesis via NF-κB signaling.
    Wen J; Yang S; Yan G; Lei J; Liu X; Zhang N; Zhang J; Deng H; Wu L; Li Y
    Exp Cell Res; 2023 Jul; 428(2):113651. PubMed ID: 37201744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exosomes synergized with PIONs@E6 enhance their immunity against hepatocellular carcinoma via promoting M1 macrophages polarization.
    Chen H; Jiang S; Zhang P; Ren Z; Wen J
    Int Immunopharmacol; 2021 Oct; 99():107960. PubMed ID: 34284286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.
    Zhou C; Weng J; Liu C; Liu S; Hu Z; Xie X; Gao D; Zhou Q; Sun J; Xu R; Li H; Shen Y; Yi Y; Shi Y; Sheng X; Dong Q; Hung MC; Ren N
    Gastroenterology; 2023 Jun; 164(7):1261-1278. PubMed ID: 36863689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
    Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
    J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
    Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
    Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
    Lin Z; Jiang C; Wang P; Chen Q; Wang B; Fu X; Liang Y; Zhang D; Zeng Y; Liu X
    Theranostics; 2023; 13(12):4166-4181. PubMed ID: 37554274
    [No Abstract]   [Full Text] [Related]  

  • 38.
    Zhao T; Zhang Z; Li Y; Sun Z; Liu L; Deng X; Guo J; Zhu D; Cao S; Chai Y; Nikolaevna UV; Maratbek S; Wang Z; Zhang H
    Front Immunol; 2023; 14():1180837. PubMed ID: 37325614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma.
    Lin L; Chen S; Wang H; Gao B; Kallakury B; Bhuvaneshwar K; Cahn K; Gusev Y; Wang X; Wu Y; Marshall JL; Zhi X; He AR
    Theranostics; 2021; 11(9):4232-4250. PubMed ID: 33754058
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.